Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 13/20 | 0.61 |
| ▸ | ITGA2B | P08514 | 13/20 | 0.61 |
| ▸ | ITGAV | P06756 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | TACR1 | P25103 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6221346 | 0.91 | ITGB3 (0.74) | ITGB3ITGA2BITGAVALDH1A1ALOX15 | |
| SCHEMBL8366724 | 0.88 | GAA (0.61) | ITGB3ITGA2BALDH1A1ALOX15HDAC8 | |
| SCHEMBL4830419 | 0.86 | ITGB3 (0.70) | ITGB3ITGA2BITGAV | |
| SCHEMBL6440663 | 0.84 | CTSL (0.64) | ALDH1A1ALOX15TACR1 | |
| SCHEMBL6440666 | 0.84 | CTSL (0.64) | ALDH1A1ALOX15TACR1 | |
| SCHEMBL3131881 | 0.84 | ITGB3 (0.67) | ITGB3ITGA2BITGAVALDH1A1ALOX15 | |
| SCHEMBL14370509 | 0.84 | ATM (0.60) | ITGB3ITGA2BALDH1A1ALOX15HDAC8 | |
| SCHEMBL5175372 | 0.84 | ITGB3 (0.61) | ITGB3ITGA2BITGAV | |
| SCHEMBL6341457 | 0.83 | ITGB3 (0.51) | ITGB3ITGA2BITGAVHDAC8 | |
| SCHEMBL11199738 | 0.82 | CTSL (0.62) | ALDH1A1ALOX15TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6838453-B2 | Antagonist derivatives of the vitronectin receptor | AVENTIS PHARMA S.A. (FR) | 2005-01-04 | — | — | US | disclosed |
| US-20040225111-A1 | ANTAGONIST DERIVATIVES OF THE VITRONECTIN RECEPTOR | AVENTIS PHARMA S.A. (FR) | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040225111-A1 | ANTAGONIST DERIVATIVES OF THE VITRONECTIN RECEPTOR | ADGRF1, BDKRB1, ADGRE5 | ITGB3 220/4885ITGA2B 117/4885ITGAV 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.